The effect of regression of cirrhosis in chronic Hepatitis C is unknown.
Dr Vincent Mallet and colleagues from France evaluated the relation between regression of cirrhosis and clinical outcome in patients with chronic Hepatitis C after antiviral therapy.
A cohort of patients with cirrhosis were treated between 1988 and 2001, and followed to 2006.
|The combined end point per 100 patient-years was 4 in patients without regression of cirrhosis|
|Annals of Internal Medicine|
The team treated 96 patients with chronic Hepatitis C and biopsy-proven cirrhosis with an interferon-based regimen, and who had at least 1 posttreatment liver biopsy.
The team evaluated occurrence of a combined end point of liver-related events, and death in patients with regression of cirrhosis.
The researchers reported that the median follow-up was 118 months, and 18 patients had regression of cirrhosis.
The incidence of the combined end point per 100 patient-years was 0 in patients with regression of cirrhosis and 4 in patients without regression of cirrhosis.
The transplantation-free survival rate at 10 years was 100% in patients with regression of cirrhosis, and 74% in patients without regression of cirrhosis.
The team reported that the low number of patients who experienced regression of cirrhosis precludes analysis of factors that could predict regression of cirrhosis.
Dr Mallet’s team concluded, “Regression of cirrhosis occurs after antiviral therapy in some patients with chronic Hepatitis C.”
“Regression is associated with decreased disease-related morbidity and improved survival.”